PATENT CLAIM ANALYSIS

Application Number: 16030204
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "186100"]

Abstract:
The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E 1 B gene product, expressed from the E 1 B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E 1 B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.

Claim (Index 40):
The method of  claim 34 , wherein the recombinant adenovirus carries a mutation in the sequence of the E1B gene of the adenovirus and the mutation in the E1B gene is A3216G wherein the numbering is relative to the adenovirus Ad5 genome (accession number AC_000008.1) (SEQ ID NO: 41) (position 1503 in the E1B gene (SEQ ID NO: 1)) or a guanine point mutation at an equivalent position to 3216 in any other adenovirus serotype.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 95.0
- Lexical Diversity: 1.61017
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14648661', '13254825', '10669768', '09351778', '12561016']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7553578170611761
- 35 USC 102 Novelty (BERT): 0.7046869178448247
- Combined Prediction Score: 0.7502907271395409
- Mean Citation Score: 516.8528660000002
- Max Citation Score: 883.802
- Similarity Product: 702.2894119455815

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test